“There is a race to the middle between pharma and food. The opportunity is big. The risk is big. The reward is big.”

—LUIS CANTRELL, head of business at Nestle SA, explaining why the company sat on $28.3 billion in cash this year instead of acquiring or investing in troubled businesses, as its competitors did. Instead, Cantrell said, Nestle focused its spending on advances in nutrition products in a bid to compete with pharmaceutical companies [via Bloomberg]